Claim CME

Research, Methods, Statistics

Randomized Clinical Trials and COVID-19Managing Expectations

Educational Objective
To understand how Clinical Trials are being used to manage COVID-19

1 Credit CME

JAMA

Published Online: May 4, 2020

Editorial

Article Information and Disclosures

Howard Bauchner, MD¹;

Phil B. Fontanarosa, MD, MBA²

Author Affiliations

¹Editor in Chief, JAMA, Chicago, Illinois
²Executive Editor, JAMA, Chicago, Illinois

Read article on JAMA Network

Read Article Claim CME

Despite the millions of cases and hundreds of thousands of deaths that have occurred in this devastating coronavirus disease 2019 (COVID-19) pandemic, no peer-reviewed studies of specific therapies proven to be effective in reducing mortality have been published and a vaccine is many months to years away. To date, more than 1000 studies addressing various aspects of COVID-19 are registered on ClinicalTrials.gov, including more than 600 interventional studies and randomized clinical trials (RCTs).¹ During the next few weeks and months, the results of numerous RCTs involving therapies for COVID-19 will be reported. Indeed, preliminary results from some studies have already been reported in social media and the popular press. How will clinicians, the public, and politicians understand the results of these much-anticipated and critically needed clinical trials?

Claim CME

Buy This Activity

Article Information

Corresponding Author: Howard Bauchner, MD, JAMA, 330 N Wabash Ave, Chicago, IL 60611 (Howard.Bauchner@jamanetwork.org).

Published Online: May 4, 2020. doi:10.1001/jama.2020.8115

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank Derek C. Angus, MD, MPH (associate editor, JAMA), and Rob Golub, MD (deputy editor, JAMA), for their valuable comments.

References

US National Library of Medicine. ClinicalTrials.gov. Accessed April 30, 2020. https://clinicaltrials.gov/

Randomized Clinical Trials and COVID-19Managing Expectations

Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics

Preserving Clinical Trial Integrity During the Coronavirus Pandemic

Optimizing the Trade-off Between Learning and Doing in the COVID-19 Pandemic

Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic

Conducting Clinical Research During the COVID-19 Pandemic

Maintaining Quality of Editorial Evaluation and Peer Review

Pooling Data From Individual Clinical Trials in the COVID-19 Era

See More

Randomized Clinical Trials and COVID-19Managing Expectations

Treating COVID-19—Off-Label and Compassionate Use and Clinical Trials During Pandemics

Preserving Clinical Trial Integrity During the Coronavirus Pandemic

Optimizing the Trade-off Between Learning and Doing in the COVID-19 Pandemic

Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic

Conducting Clinical Research During the COVID-19 Pandemic

Maintaining Quality of Editorial Evaluation and Peer Review

Pooling Data From Individual Clinical Trials in the COVID-19 Era

See More

See More About

Want full access to the AMA Ed Hub?

AMA Membership provides:

Sign in to access

Want full access to the AMA Ed Hub?

Sign in to customize your interests

With a personal account, you can:

Name Your Search

Sign in to save your search

With a personal account, you can:

Lookup An Activity

My Saved Searches

My Saved Courses

Purchase access